As an innovative representative of modern drug delivery systems, injection pens play a central role in the treatment of chronic diseases such as diabetes, growth hormone deficiency, and obesity. Their features—accurate dosing, ease of operation, and high patient compliance—perfectly meet the long-term injection needs of protein-based drugs like insulin, growth hormone, and benaglutide. This article provides an in-depth analysis of the synergistic development path between injection pens and key biological agents from three perspectives: technical compatibility, clinical application value, and regulatory framework.
I. Technical Compatibility: Addressing Core Challenges in Protein-Based Drug Delivery
The design of injection pens specifically overcomes the unique delivery challenges of protein-based drugs:
Precise Dose Control
Insulin: Different types (rapid-acting, long-acting, premixed) require fine adjustments as small as 0.5–1 unit. The mechanical/electronic dose selection system of insulin pens avoids reading errors common with traditional syringes.
Growth hormone: Pediatric doses need fine adjustments based on body weight (typically 0.1–0.3 mg/kg/day). The pen design significantly reduces the risk of dosing errors.
Benaglutide: As a GLP-1 analog, it requires stepwise dose escalation (e.g., 0.2 mg → 0.4 mg → 0.6 mg). Prefilled pens can preset fixed incremental doses.
Enhanced Patient Compliance
Integrated needles, concealed drug solutions, and one-button injection designs alleviate patients’ fear of traditional injections, especially benefiting children (growth hormone) and patients requiring multiple daily injections (insulin, benaglutide). Some products are equipped with memory functions (e.g., recording the time/dose of the last injection) to assist medication management.
Drug Stability Assurance
Injection pens use sealed cartridges to minimize contact between the drug solution and air, reducing the risk of protein oxidation and aggregation.
Built-in glass materials are compatible with high-concentration protein formulations (e.g., U200/U300 insulin, high-concentration growth hormone), extending efficacy and reducing injection volume.
II. Regulatory Framework: Full Lifecycle Quality Control
Global drug regulatory agencies (NMPA, FDA, EMA) classify injection pens as "drug-device combination products" and implement dual oversight:
Registration and Approval Requirements
Pharmaceutical data: Stability of the drug in the pen system (temperature, shaking, light exposure), compatibility (leachables/adsorption studies), and delivery performance (dose accuracy, repeatability) must be demonstrated.
Device performance: Mechanical reliability (drop testing, button lifespan), dose accuracy (full-range testing), and safety (needle protection, misuse prevention) are verified according to the ISO 11608 series of standards.
Human factors engineering (Usability): Simulation of real-world usage scenarios is mandatory to ensure safe and independent operation by patients of all ages and abilities (e.g., those with visual impairments).
Good Manufacturing Practices (GMP/CGMP)
Sterility assurance: Drug filling (Grade A environment under Grade C background) and needle assembly must comply with sterile process requirements.
Process control: Dimensional tolerances and assembly torque of key components (springs, gaskets) directly affect dose accuracy and require SPC statistical monitoring.
Supply chain traceability: A Unique Device Identification (UDI) system must be established for device components (cartridges, pen cores, needles).
Post-Market Surveillance Focus
Adverse events related to drug-device interactions (e.g., mechanical failures causing under-/over-dosing, needle clogging).
Real-world monitoring of dose accuracy (especially for high-concentration formulations).
Compliance of patient training materials (e.g., EMA requires multimedia operation guides).
Features of Chinese Regulations (NMPA)
The "Rules for the Unique Device Identification System" require UDI labeling for prefilled pens.
The "Technical Guidelines for Drug-Device Combination Products" clarify the evaluation pathway for drug-device interactions.
New regulations in 2023 strengthen requirements for human factors engineering and usability testing, aligning with international standards.
III. Typical Case Studies
Insulin pens: From first-generation pens with replaceable cartridges to smart connected pens, continuous optimization of dose memory and data tracking functions meets personalized diabetes management needs.
Growth hormone pens: Hidden needle designs significantly reduce injection anxiety in children, while automatic recording functions assist in growth curve monitoring.
GLP-1 receptor agonist pens: Benaglutide prefilled pens use a multi-dose prefilled design to simplify medication processes; semaglutide pens feature a dose selector separated from the injection button to reduce operational errors.
Injection pens have reshaped the treatment experience for protein-based drugs through technological innovation, becoming a core tool in chronic disease management. Their development and production must strictly adhere to the dual regulatory framework for "drug-device combination products," ensuring pharmaceutical efficacy and device reliability while continuously optimizing human-machine interaction design and smart functions. As regulatory agencies like the NMPA refine requirements for combination products, pharmaceutical companies must strengthen interdisciplinary collaboration (pharmaceuticals + engineering + human factors science) and build a quality system covering the entire lifecycle to promote the implementation of safer, more accurate, and more convenient protein drug delivery solutions.
Copyright © Shijiazhuang Xinfuda Medical Packaging Co., Ltd. All Rights
MAKE AN ENQUIRY
